1 / 18

Fibrinoid necrosis in a Rhesus macaque

Fibrinoid necrosis in a Rhesus macaque. Karen Strait, Dan Anderson, and Elizabeth Strobert Yerkes National Primate Research Center Emory University. History. Signalment: ~5 year old, male, rhesus macaque Assigned to renal transplant study

curry
Download Presentation

Fibrinoid necrosis in a Rhesus macaque

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Fibrinoid necrosis in a Rhesus macaque Karen Strait, Dan Anderson, and Elizabeth Strobert Yerkes National Primate Research Center Emory University Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  2. History • Signalment: ~5 year old, male, rhesus macaque • Assigned to renal transplant study • Left nephrectomy followed by right nephrectomy and allogeneic renal transplant 5 months later • Received sirolimus and Cremophor EL vehicle beginning the day of transplantation • Control Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  3. History • Clinical findings following renal transplant • Right kidney prominent and firm • Scrotal edema/perineal edema, absent by post-op day 14 • Intermittent diarrheal episodes, treated with appropriate antibiotics • Occasional periorbital edema • Thrombocytopenia at day 38 post-op • Poor appetite/weight loss at 40 days post-op • Animal euthanized due to a deteriorating clinical condition Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  4. Gross Findings Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  5. Gross findings Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  6. Histopathology Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  7. Histopathology Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  8. Histopathology Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  9. Histopathology Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  10. Histopathology Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  11. Histopathology Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  12. Diagnosis • Morphologic diagnosis: multifocal severe fibrinoid necrosis of submucosal arteries with edema and thickening of associated tissues Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  13. Discussion • Cause is undetermined • Possible association with drug regimen in this animal model Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  14. Discussion • Sirolimus • Immunosuppressive/ anti-rejection drug • Non-nephrotoxic • Fibrinoid necrosis in GI previously reported in rhesus macaques receiving sirolimus, tacrolimus, and daclizumab to prevent renal allograft rejection – attributed to sirolimus toxicity • Link between sirolimus and fibrinoid necrosis shown in some species, absent in others • Not seen in other transplant studies at Yerkes Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  15. Discussion • Cremophor EL • Vehicle for hydrophobic drugs • Not inert • May change pharmacological profile of drugs administered with it • Unknown interaction between Cremophor EL and sirolimus • Fibrinoid necrosis not reported with this drug • Combination of animal model, sirolimus and Cremophor EL?? Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  16. Acknowledgements • Eileen Breding • Evan Dessasau Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  17. References 1. Gelderblom, H., J. Verweij, K. Nooter, A. Sparreboom. 2001. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 37(13):1590-8. 2. Montgomery, S.P., S.R. Mog, H. Xu, D.K. Tadaki, B. Hirshberg, J.D. Berning, J. Leconte, D.M. Harlan, D. Hale, A.D. Kirk. 2002. Efficacy and toxicity of a protocol using sirolimus, tacrolimus, and daclizumab in a nonhuman primate renal allotransplant model. Am J Transplant. 2(4):381-5. Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

  18. Questions? Presented at SEVPAC 2008 – Permission granted for use on SEVPAC website only

More Related